IN2014CN04590A - - Google Patents

Download PDF

Info

Publication number
IN2014CN04590A
IN2014CN04590A IN4590CHN2014A IN2014CN04590A IN 2014CN04590 A IN2014CN04590 A IN 2014CN04590A IN 4590CHN2014 A IN4590CHN2014 A IN 4590CHN2014A IN 2014CN04590 A IN2014CN04590 A IN 2014CN04590A
Authority
IN
India
Prior art keywords
nucleic acid
acid strand
nucleotides
nucleotide analogs
transcription product
Prior art date
Application number
Inventor
Takanori Yokota
Kazutaka Nishina
Satoshi Obika
Hidehiro Mizusawa
Original Assignee
Nat Univ Corp Tokyo Med & Dent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Univ Corp Tokyo Med & Dent filed Critical Nat Univ Corp Tokyo Med & Dent
Publication of IN2014CN04590A publication Critical patent/IN2014CN04590A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/52—Methods for regulating/modulating their activity modulating the physical stability, e.g. GC-content

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Disclosed are double stranded nucleic acid complexes that suppress the expression of a target gene by means of an antisense effect and methods for using the same. One method for reducing the level of a transcription product in a cell comprises contacting with the cell a composition comprising: a double stranded nucleic acid complex comprising a first nucleic acid strand annealed to a second nucleic acid strand wherein: the first nucleic acid strand (i) comprises nucleotides and optionally nucleotide analogs and the total number of nucleotides and nucleotide analogs in the first nucleic acid strand is from 8 to 100 (ii) comprises at least 4 consecutive nucleotides that are recognized by RNase H when the first nucleic acid strand is hybridized to the transcription product and (iii) the first nucleic acid strand hybridizes to the transcription product; and the second nucleic acid strand comprises nucleotides and optionally nucleotide analogs.
IN4590CHN2014 2011-12-16 2012-12-17 IN2014CN04590A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011275488 2011-12-16
PCT/JP2012/083180 WO2013089283A1 (en) 2011-12-16 2012-12-17 Chimeric double-stranded nucleic acid

Publications (1)

Publication Number Publication Date
IN2014CN04590A true IN2014CN04590A (en) 2015-09-18

Family

ID=47559626

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4590CHN2014 IN2014CN04590A (en) 2011-12-16 2012-12-17

Country Status (9)

Country Link
US (6) US9816089B2 (en)
EP (1) EP2791335B1 (en)
JP (7) JP6112569B2 (en)
CN (2) CN104126010B (en)
AU (1) AU2012353330B2 (en)
CA (2) CA3106312C (en)
ES (1) ES2707232T3 (en)
IN (1) IN2014CN04590A (en)
WO (1) WO2013089283A1 (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2451461A4 (en) 2009-07-06 2013-05-29 Ontorii Inc NOVEL NUCLEIC ACID PRECURSORS AND THEIR METHODS OF USE
DK2620428T3 (en) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetric help group
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
ES2707232T3 (en) * 2011-12-16 2019-04-03 Univ Nat Corp Tokyo Medical & Dental Chimeric double-stranded nucleic acid
DK2872485T3 (en) 2012-07-13 2021-03-08 Wave Life Sciences Ltd ASYMMETRIC ASSISTANCE GROUP
WO2014132671A1 (en) * 2013-03-01 2014-09-04 National University Corporation Tokyo Medical And Dental University Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent
JP6300212B2 (en) * 2013-03-21 2018-03-28 国立大学法人 東京医科歯科大学 Double-stranded nucleic acid binding agent, binding agent-double-stranded nucleic acid complex, pharmaceutical composition containing the complex, and method for producing the complex
EP3010514B1 (en) * 2013-06-16 2021-01-20 National University Corporation Tokyo Medical and Dental University Double-stranded antisense nucleic acid with exon-skipping effect
WO2015105083A1 (en) * 2014-01-07 2015-07-16 塩野義製薬株式会社 Double-stranded oligonucleotide containing antisense oligonucleotide and sugar derivative
US9714288B2 (en) 2014-09-30 2017-07-25 The Regents Of The University Of California Antisense compounds and uses thereof
WO2016161388A1 (en) 2015-04-03 2016-10-06 University Of Massachusetts Fully stabilized asymmetric sirna
WO2017030973A1 (en) 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
JP2018528783A (en) 2015-09-25 2018-10-04 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Conjugate antisense compounds and uses thereof
US20180228830A1 (en) * 2015-10-23 2018-08-16 Rena Therapeutics Inc. Nucleic acid complex having at least one bulge structure
US20180223280A1 (en) * 2015-10-23 2018-08-09 Rena Therapeutics Inc. Nucleic acid complex
WO2017094745A1 (en) * 2015-12-01 2017-06-08 国立大学法人大阪大学 Composition including nucleic acid for enteral administration
CN116064544A (en) * 2016-01-26 2023-05-05 日产化学株式会社 single stranded oligonucleotide
KR102775461B1 (en) * 2016-04-01 2025-02-28 어비디티 바이오사이언시스 인크. Nucleic acid-polypeptide compositions and uses thereof
US11433089B2 (en) * 2016-09-23 2022-09-06 National University Corporation Tokyo Medical And Dental University Blood-brain barrier permeable heteroduplex nucleic acid
JP7129702B2 (en) 2016-09-29 2022-09-02 国立大学法人 東京医科歯科大学 Double-stranded nucleic acid complex with overhangs
US11572558B2 (en) 2017-02-06 2023-02-07 Nissan Chemical Corporation Single-stranded oligonucleotide
JP7190794B2 (en) 2017-03-29 2022-12-16 塩野義製薬株式会社 Complex of nucleic acid medicine and hyperbranched lipid
WO2018180005A1 (en) * 2017-03-31 2018-10-04 国立研究開発法人日本医療研究開発機構 Antisense nucleic acid for inhibiting biosynthesis of chondroitin sulfate
EP3647423A4 (en) * 2017-06-30 2021-03-24 National University Corporation Tokyo Medical and Dental University STRAIGHT DOUBLE-STRANDED ANTI-MIRROR
TWI902655B (en) * 2017-07-26 2025-11-01 日商日產化學股份有限公司 Single-stranded oligonucleotides
EP3724206B1 (en) 2017-12-14 2023-06-28 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
JP7360170B2 (en) 2018-02-28 2023-10-12 国立大学法人 東京医科歯科大学 Ischemic lesion site-specific gene therapy
KR20190110043A (en) * 2018-03-19 2019-09-27 주식회사 케이티 Method and apparatus for processing video signal
JP7333079B2 (en) 2018-03-19 2023-08-24 国立大学法人 東京医科歯科大学 Nucleic acids with reduced toxicity
CN111868244A (en) 2018-03-20 2020-10-30 国立大学法人东京工业大学 Antisense oligonucleotides with reduced toxicity
WO2019182109A1 (en) * 2018-03-22 2019-09-26 国立大学法人東京医科歯科大学 Bbb-passing lipid ligand of hetero nucleic acid
WO2020150636A1 (en) 2019-01-18 2020-07-23 University Of Massachusetts Dynamic pharmacokinetic-modifying anchors
WO2020209285A1 (en) 2019-04-08 2020-10-15 国立大学法人東京医科歯科大学 Pharmaceutical composition for muscle disease treatment
WO2021020412A1 (en) 2019-07-30 2021-02-04 塩野義製薬株式会社 Nucleic acid drug targeting murf1
US20240117346A1 (en) * 2019-10-11 2024-04-11 National University Corporation Tokyo Medical And Dental University Modified hetero nucleic acids
EP4090744A4 (en) * 2020-01-17 2024-04-10 Anastasia Khvorova Universal dynamic pharmacokinetic-modifying anchors
US20230127437A1 (en) 2020-01-31 2023-04-27 Sanwa Kagaku Kenkyusho Co., Ltd. Antisense oligonucleotide of atn1
JPWO2021177418A1 (en) 2020-03-04 2021-09-10
EP4123023A4 (en) 2020-03-16 2024-07-17 National University Corporation Tokyo Medical and Dental University HETERO-NUCLEIC ACID CONTAINING MORPHOLINO NUCLEIC ACID
EP4157289A4 (en) 2020-05-26 2024-06-26 University Of Massachusetts SYNTHETIC OLIGONUCLEOTIDES WITH BLOCK AND CLUSTER MODIFICATION REGIONS
CN115968374A (en) 2020-06-15 2023-04-14 Liid制药股份有限公司 Cross-linked nucleosides and nucleotides
CA3202708A1 (en) 2020-11-23 2022-05-27 Alpha Anomeric Sas Nucleic acid duplexes
WO2022183102A1 (en) * 2021-02-26 2022-09-01 Northwestern University Cell-free biosensors with dna strand displacement circuits
CA3221584A1 (en) * 2021-05-25 2022-12-01 National University Corporation Tokyo Medical And Dental University Heteronucleic acid containing scpbna or amna
WO2022255273A1 (en) 2021-05-31 2022-12-08 レナセラピューティクス株式会社 Ligand-bound nucleic acid complex
WO2023022229A1 (en) 2021-08-19 2023-02-23 国立大学法人東京医科歯科大学 Modified heteronucleic acid containing morpholino nucleic acid
US20240390508A1 (en) 2021-08-21 2024-11-28 Takeda Pharmaceutical Company Limited Human transferrin receptor binding peptide-drug conjugate
WO2023042876A1 (en) 2021-09-15 2023-03-23 国立大学法人東京医科歯科大学 Heteronucleic acid including 2'-modified nucleoside
WO2023064937A1 (en) * 2021-10-14 2023-04-20 Arizona Board Of Regents On Behalf Of Arizona State University Programmable delivery platforms for rna structures
WO2023080159A1 (en) 2021-11-02 2023-05-11 レナセラピューティクス株式会社 Ligand-bound nucleic acid complex
US20250297249A1 (en) * 2021-12-07 2025-09-25 Liid Pharmaceuticals, Inc. Antisense oligonucleotide complex
JPWO2024071099A1 (en) 2022-09-29 2024-04-04
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes
WO2024228398A1 (en) * 2023-05-02 2024-11-07 国立大学法人東京医科歯科大学 Nucleic acid agent for inducing g-quadruplex structure
TW202516006A (en) 2023-08-30 2025-04-16 日商Ｓｔｒａｔｏｉｍｍｕｎｅ股份有限公司 RasGRP4 antisense oligonucleotide

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09110894A (en) * 1995-10-17 1997-04-28 Soyaku Gijutsu Kenkyusho:Kk Hybric dna/rna oligonucleotide and antiviral agent
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
JP3781879B2 (en) 1996-11-18 2006-05-31 武 今西 Novel nucleotide analogues
JP3756313B2 (en) 1997-03-07 2006-03-15 武 今西 Novel bicyclonucleosides and oligonucleotide analogues
CA2303299C (en) 1997-09-12 2016-02-23 Exiqon A/S Oligonucleotide analogues
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US20060074034A1 (en) * 2001-09-17 2006-04-06 Collins Douglas A Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof
FR2832154B1 (en) * 2001-11-09 2007-03-16 Centre Nat Rech Scient OLIGONUCLEOTIDES INHIBITORS AND THEIR USE FOR SPECIFICALLY REPRESSING A GENE
AU2002249967A1 (en) 2001-11-12 2003-05-26 Epiclone, Inc. Gene silencing using sense dna and antisense rna hybrid constructs
AU2003247521A1 (en) * 2002-06-26 2004-01-19 Isis Pharmaceuticals, Inc. Antisense inhibition via rnase h-independent reduction in mrna
DE10240417A1 (en) 2002-09-02 2004-03-11 Avontec Gmbh Decoy oligonucleotide inhibition of CD40 expression
WO2004027030A2 (en) * 2002-09-18 2004-04-01 Isis Pharmaceuticals, Inc. Efficient reduction of target rna’s by single- and double-stranded oligomeric compounds
EP2336318B1 (en) * 2002-11-13 2013-04-24 Genzyme Corporation Antisense modulation of apolipoprotein b expression
EP1661905B9 (en) 2003-08-28 2012-12-19 IMANISHI, Takeshi Novel artificial nucleic acids of n-o bond crosslinkage type
SG146682A1 (en) * 2003-09-18 2008-10-30 Isis Pharmaceuticals Inc Modulation of eif4e expression
US20050244869A1 (en) * 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
AU2011204898A1 (en) * 2004-04-09 2011-08-11 Biodelivery Sciences International, Inc Nucleotide-cochleate compositions and methods of use
WO2005113571A2 (en) * 2004-05-13 2005-12-01 The University Of North Carolina At Chapel Hill Methods for the delivery of oligomeric compounds
MX2007008065A (en) 2004-12-30 2008-03-04 Todd M Hauser Compositions and methods for modulating gene expression using self-protected oligonucleotides.
DK2021472T3 (en) 2006-05-05 2011-09-19 Isis Pharmaceuticals Inc Compounds and Methods for Modeling Gene Expression
KR20090064378A (en) 2006-08-10 2009-06-18 온코세라피 사이언스 가부시키가이샤 Breast Cancer Related Genes and Polypeptides
WO2008029619A1 (en) 2006-09-07 2008-03-13 Daiichi Sankyo Company, Limited Ena antisense oligonucleotide having sequence-specific action
EP2076597A2 (en) 2006-10-09 2009-07-08 Santaris Pharma A/S Rna antagonist compounds for the modulation of pcsk9
US8093222B2 (en) * 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US7858592B2 (en) * 2007-02-26 2010-12-28 The Board Of Regents Of The University Of Texas System Interfering RNAs against the promoter region of P53
US8461124B2 (en) * 2007-03-15 2013-06-11 Jyoti Chattopadhyaya Five- and six-membered conformationally locked 2′,4′-carbocyclic ribo-thymidines for the treatment of infections and cancer
WO2009099326A1 (en) * 2008-02-08 2009-08-13 Prosensa Holding Bv Methods and means for treating dna repeat instability associated genetic disorders
EP2133425A1 (en) * 2008-06-13 2009-12-16 Karin Mölling Method and compound for antiviral (HIV) therapy
US8541569B2 (en) * 2008-09-06 2013-09-24 Chemgenes Corporation Phosphoramidites for synthetic RNA in the reverse direction, efficient RNA synthesis and convenient introduction of 3'-end ligands, chromophores and modifications of synthetic RNA
DK3252068T3 (en) * 2009-10-12 2025-08-25 Larry J Smith METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION USING OLIGONUCLEOTIDE-BASED DRUGS ADMINISTERED IN VIVO OR IN VITRO
ES2707232T3 (en) * 2011-12-16 2019-04-03 Univ Nat Corp Tokyo Medical & Dental Chimeric double-stranded nucleic acid
EP3004347B1 (en) * 2013-05-30 2018-09-26 National University Corporation Tokyo Medical and Dental University Double-stranded agents for delivering therapeutic oligonucleotides

Also Published As

Publication number Publication date
AU2012353330B2 (en) 2018-04-19
JP2022000426A (en) 2022-01-04
JP2018203779A (en) 2018-12-27
US10329567B2 (en) 2019-06-25
JP7174384B2 (en) 2022-11-17
ES2707232T3 (en) 2019-04-03
CA3106312A1 (en) 2013-06-20
JP2017140031A (en) 2017-08-17
JP6638923B2 (en) 2020-02-05
JP6960123B2 (en) 2021-11-05
JP2022171811A (en) 2022-11-11
US20180073024A1 (en) 2018-03-15
CN112386605A (en) 2021-02-23
US20140302603A1 (en) 2014-10-09
CA3106312C (en) 2025-09-23
US11034955B2 (en) 2021-06-15
CA2859581A1 (en) 2013-06-20
JP6416301B2 (en) 2018-10-31
EP2791335B1 (en) 2018-11-14
JP2021011501A (en) 2021-02-04
US9816089B2 (en) 2017-11-14
CA2859581C (en) 2022-03-22
JP2015502134A (en) 2015-01-22
JP7423015B2 (en) 2024-01-29
US20180320181A1 (en) 2018-11-08
US20240158790A1 (en) 2024-05-16
US20210340540A1 (en) 2021-11-04
WO2013089283A1 (en) 2013-06-20
EP2791335A1 (en) 2014-10-22
US12344841B2 (en) 2025-07-01
CN104126010A (en) 2014-10-29
CN104126010B (en) 2021-04-06
JP6112569B2 (en) 2017-04-12
JP2020039364A (en) 2020-03-19
US10337006B2 (en) 2019-07-02
AU2012353330A1 (en) 2014-07-31
US20190270996A1 (en) 2019-09-05

Similar Documents

Publication Publication Date Title
HK1221978A1 (en) Tmprss6 irna compositions and methods of use thereof
IN2013MN00522A (en)
MY201125A (en) Novel promoter and method for producing purine nucleotide using the same
EP2580355A4 (en) INVERSE TRANSCRIPTION TO MEDIATION BY MODIFIED LOOP-RING OLIGONUCLEOTIDE AND RESTRICTED QUANTITATIVE PCR WITH BASIC SPACING
EP3693464A3 (en) Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes
WO2010080129A3 (en) Extended dicer substrate agents and methods for the specific inhibition of gene expression
NZ593618A (en) Gnaq targeted dsrna compositions and methods for inhibiting expression
NZ627060A (en) Polynucleotide molecules for gene regulation in plants
WO2011123621A3 (en) 2' and 5' modified monomers and oligonucleotides
WO2012142611A3 (en) Sequencing small amounts of complex nucleic acids
SG170780A1 (en) Compositions and methods for inhibiting expression of eg5 gene
WO2012046085A3 (en) Methods of inducing insulin production
SG10201804076RA (en) Methods for multiplex detection of alleles associated with ophthalmic conditions
NZ601247A (en) Targeted genomic alteration
JP2012050447A5 (en)
TN2015000079A1 (en) Antisense polynucleotides to induce exon skipping and methods of treating dystrophies
WO2012168307A3 (en) Improved recombination efficiency by inhibition of nhej dna repair
WO2012078967A3 (en) Compositions and methods for increasing erythropoietin (epo) production
WO2010006973A3 (en) Compositions and methods for inhibiting expression of tgf-beta receptor genes
WO2012178033A3 (en) Serpina1 sirnas: compositions of matter and methods of treatment
WO2012177949A3 (en) Compositions and methods for inhibition of expression of protein c (proc) genes
Cortez et al. microRNAs in cancer: from bench to bedside
WO2007147067A3 (en) Methods and compositions for regulating cell cycle progression
WO2009086428A3 (en) Methods and compositions for increasing gene expression
MX2019009305A (en) Single-stranded oligonucleotide.